RECENT PHARMACOLOGICAL ADVANCES IN THE TREATMENT OF TUBERCULOSIS: AN UPDATED NARRATIVE BIBLIOGRAPHICAL REVIEW

• DOI: https://doi.org/10.22533/at.ed.1594122423012

• Palavras-chave: Tuberculosis, Treatment, New Drugs.

• Keywords: Tuberculosis, Treatment, New Drugs.

• Abstract:

  Goal: To evaluate recent pharmacological advances in the treatment of tuberculosis, focusing on their efficacy, safety and potential impact on clinical practice. Methods: This is a Narrative Bibliographic Review carried out using the PubMed database platform. The search was constructed using the descriptors “tuberculosis”, “management”, “treatment strategy” and “new drugs”, in association with the Boolean operators “AND” and “OR” and “NOT”, resulting in 2126 initial articles. Due to the inclusion and exclusion criteria, only 26 became official sources. Discussion: The treatment of multidrug-resistant tuberculosis benefits from medications such as Bedaquiline, which offer efficacy and a reduction in treatment time. However, these medications raise concerns due to side effects significant side effects such as changes in the electrocardiogram and cardiotoxicity. The BPAZ regimen has been observed to react variously to changes in exposure to pyrazinamide and Bedaquiline. Additionally, the development of innovative technologies such as vaccines to prevent TB reinfection and immunotherapies to strengthen the immune response against latent tuberculosis is in focus, aiming to shorten the duration of the disease and prevent bacterial resistance. Final Considerations: The need to develop more effective and safe therapeutic options for the treatment of tuberculosis and its resistance is evident. Understanding both the benefits and adverse effects of current drugs is crucial. Furthermore, vaccines and emerging immunotherapies promise to strengthen the immune system, prevent reinfections and combat resistance to tuberculosis, representing significant interventions in the fight against the disease.